I recently warned you about the detrimental effect that high interest rates could have on the valuation of Johnson & Johnson (NYSE:JNJ), but here I'll focus on a couple of side risks I barely touched upon in my recent coverage of this $316bn market-cap behemoth, which so far includes:

• What To Make Of Johnson & Johnson At $118 In The Wake Of Q3 Results (18 October)
• How Johnson & Johnson Could Plummet To $98 (17 October)

Remicade

READ FULL ARTICLE HERE